Arimidex

Drug Status: Marketed Drug

Arimidex™ (anastrozole), an oral aromatase inhibitor (AI), is an endocrine (hormonal) therapy for the treatment of hormone-sensitive breast cancer in postmenopausal women. ARIMIDEX was first launched in 1995 for the treatment of advanced disease and the first approvals for early breast cancer treatment followed in 2002.

For further information on Arimidex and links to other product specific and disease area websites please click here.

Please consult the prescribing information for the country concerned on the approved use of drug.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.